246 related articles for article (PubMed ID: 30802932)
1. Oncology Therapy Drugs in China, Japan, and the United States: Pharmacokinetic Characteristics, Dose Regimens, and Development Strategies.
Zhou L; Higashimori M; Shen K; Zhang Z; Sheng J; Xu H; Horiuchi M; Ichikawa K; Al-Huniti N; Zhou D
Clin Pharmacol Ther; 2019 Jun; 105(6):1303-1320. PubMed ID: 30802932
[No Abstract] [Full Text] [Related]
2. Clinical and Regulatory Aspects of Companion Diagnostic Development in Oncology.
Jørgensen JT; Hersom M
Clin Pharmacol Ther; 2018 Jun; 103(6):999-1008. PubMed ID: 29197081
[TBL] [Abstract][Full Text] [Related]
3. Challenges and Opportunities With Oncology Drug Development in China.
Bajaj G; Gupta M; Wang HH; Barrett JS; Tan M; Rupalla K; Bertz R; Sheng J
Clin Pharmacol Ther; 2019 Feb; 105(2):363-375. PubMed ID: 29328503
[TBL] [Abstract][Full Text] [Related]
4. A Significant Anticancer Drug Approval Lag Between Japan and the United States Still Exists for Minor Cancers.
Yamashita K; Kaneko M; Narukawa M
Clin Pharmacol Ther; 2019 Jan; 105(1):153-160. PubMed ID: 29882302
[TBL] [Abstract][Full Text] [Related]
5. Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology.
Ji Y; Jin JY; Hyman DM; Kim G; Suri A
Clin Transl Sci; 2018 Jul; 11(4):345-351. PubMed ID: 29392871
[No Abstract] [Full Text] [Related]
6. The importance of persistence in cancer drug development.
Mullard A
Nat Rev Drug Discov; 2021 Dec; 20(12):890-891. PubMed ID: 34764465
[No Abstract] [Full Text] [Related]
7. Oncology approvals in 2020: a year of firsts in the midst of a pandemic.
Amiri-Kordestani L; Pazdur R
Nat Rev Clin Oncol; 2021 Mar; 18(3):129-130. PubMed ID: 33514911
[TBL] [Abstract][Full Text] [Related]
8. Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Liao MZ; Lu D; Kågedal M; Miles D; Samineni D; Liu SN; Li C
Clin Pharmacol Ther; 2021 Nov; 110(5):1216-1230. PubMed ID: 33899934
[TBL] [Abstract][Full Text] [Related]
9. Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development.
Rioux N; Waters NJ
Drug Metab Dispos; 2016 Jul; 44(7):934-43. PubMed ID: 26936973
[TBL] [Abstract][Full Text] [Related]
10. Flexibility in the FDA approach to orphan drug development.
Hunter NL; Rao GR; Sherman RE
Nat Rev Drug Discov; 2017 Nov; 16(11):737-738. PubMed ID: 28860647
[No Abstract] [Full Text] [Related]
11. Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review.
Li N; Huang HY; Wu DW; Yang ZM; Wang J; Wang JS; Wang SH; Fang H; Yu Y; Bai Y; Yan Z; Cao Y; Jiang M; Liu YF; Li KY; Xu BH; Sun Y; He J
Lancet Oncol; 2019 Nov; 20(11):e619-e626. PubMed ID: 31674320
[TBL] [Abstract][Full Text] [Related]
12. Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development.
Faucette S; Wagh S; Trivedi A; Venkatakrishnan K; Gupta N
Clin Transl Sci; 2018 Mar; 11(2):123-146. PubMed ID: 29266809
[No Abstract] [Full Text] [Related]
13. Differences in maximum tolerated doses and approval doses of molecularly targeted oncology drug between Japan and Western countries.
Maeda H; Kurokawa T
Invest New Drugs; 2014 Aug; 32(4):661-9. PubMed ID: 24615632
[TBL] [Abstract][Full Text] [Related]
14. Oncology 2020: a drug development and approval paradigm.
Dhingra K
Ann Oncol; 2015 Nov; 26(11):2347-50. PubMed ID: 26374285
[No Abstract] [Full Text] [Related]
15. [Antibody-drug conjugates in oncology. New strategies in development].
Beck A; Dumontet C; Joubert N
Med Sci (Paris); 2019 Dec; 35(12):1043-1053. PubMed ID: 31903916
[TBL] [Abstract][Full Text] [Related]
16. Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective.
Serrano P; Hartmann M; Schmitt E; Franco P; Amexis G; Gross J; Mayer-Nicolai C
Clin Pharmacol Ther; 2019 Mar; 105(3):582-597. PubMed ID: 29923615
[TBL] [Abstract][Full Text] [Related]
17. Pediatric Development of Molecularly Targeted Oncology Drugs.
Patel SK; Leong R; Zhao H; Barone A; Casey D; Liu Q; Burckart GJ; Reaman G
Clin Pharmacol Ther; 2018 Aug; 104(2):384-389. PubMed ID: 29226303
[TBL] [Abstract][Full Text] [Related]
18. New drugs meeting in Washington: too demanding for clinicians?
Ann Oncol; 2000 Feb; 11(2):123. PubMed ID: 10761744
[No Abstract] [Full Text] [Related]
19. Dose Finding Versus Speed in Seamless Immuno-Oncology Drug Development.
Mayawala K; Tse A; Rubin EH; Jain L; de Alwis DP
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S143-S145. PubMed ID: 28921649
[No Abstract] [Full Text] [Related]
20. New drug approvals in oncology.
Kurzrock R; Kantarjian HM; Kesselheim AS; Sigal EV
Nat Rev Clin Oncol; 2020 Mar; 17(3):140-146. PubMed ID: 32020042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
